These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 22778851)

  • 1. Oral treatment with the d-enantiomeric peptide D3 improves the pathology and behavior of Alzheimer's Disease transgenic mice.
    Aileen Funke S; van Groen T; Kadish I; Bartnik D; Nagel-Steger L; Brener O; Sehl T; Batra-Safferling R; Moriscot C; Schoehn G; Horn AH; Müller-Schiffmann A; Korth C; Sticht H; Willbold D
    ACS Chem Neurosci; 2010 Sep; 1(9):639-48. PubMed ID: 22778851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer's Disease.
    Kutzsche J; Schemmert S; Tusche M; Neddens J; Rabl R; Jürgens D; Brener O; Willuweit A; Hutter-Paier B; Willbold D
    Molecules; 2017 Oct; 22(10):. PubMed ID: 28994710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increase of Positive Net Charge and Conformational Rigidity Enhances the Efficacy of d-Enantiomeric Peptides Designed to Eliminate Cytotoxic Aβ Species.
    Ziehm T; Brener O; van Groen T; Kadish I; Frenzel D; Tusche M; Kutzsche J; Reiß K; Gremer L; Nagel-Steger L; Willbold D
    ACS Chem Neurosci; 2016 Aug; 7(8):1088-96. PubMed ID: 27240424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with D3 removes amyloid deposits, reduces inflammation, and improves cognition in aged AβPP/PS1 double transgenic mice.
    van Groen T; Kadish I; Funke SA; Bartnik D; Willbold D
    J Alzheimers Dis; 2013; 34(3):609-20. PubMed ID: 23271316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deceleration of the neurodegenerative phenotype in pyroglutamate-Aβ accumulating transgenic mice by oral treatment with the Aβ oligomer eliminating compound RD2.
    Schemmert S; Schartmann E; Honold D; Zafiu C; Ziehm T; Langen KJ; Shah NJ; Kutzsche J; Willuweit A; Willbold D
    Neurobiol Dis; 2019 Apr; 124():36-45. PubMed ID: 30391539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood-brain barrier penetration of an Aβ-targeted, arginine-rich, d-enantiomeric peptide.
    Jiang N; Frenzel D; Schartmann E; van Groen T; Kadish I; Shah NJ; Langen KJ; Willbold D; Willuweit A
    Biochim Biophys Acta; 2016 Nov; 1858(11):2717-2724. PubMed ID: 27423267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. All
    Bocharov EV; Gremer L; Urban AS; Okhrimenko IS; Volynsky PE; Nadezhdin KD; Bocharova OV; Kornilov DA; Zagryadskaya YA; Kamynina AV; Kuzmichev PK; Kutzsche J; Bolakhrif N; Müller-Schiffmann A; Dencher NA; Arseniev AS; Efremov RG; Gordeliy VI; Willbold D
    J Med Chem; 2021 Nov; 64(22):16464-16479. PubMed ID: 34739758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease.
    Wang CM; Devries S; Camboni M; Glass M; Martin PT
    Neurobiol Dis; 2010 Sep; 39(3):409-22. PubMed ID: 20493257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of Alzheimer's disease amyloid plaque load in transgenic mice by D3, A D-enantiomeric peptide identified by mirror image phage display.
    van Groen T; Wiesehan K; Funke SA; Kadish I; Nagel-Steger L; Willbold D
    ChemMedChem; 2008 Dec; 3(12):1848-52. PubMed ID: 19016284
    [No Abstract]   [Full Text] [Related]  

  • 10. Aβ Oligomer Elimination Restores Cognition in Transgenic Alzheimer's Mice with Full-blown Pathology.
    Schemmert S; Schartmann E; Zafiu C; Kass B; Hartwig S; Lehr S; Bannach O; Langen KJ; Shah NJ; Kutzsche J; Willuweit A; Willbold D
    Mol Neurobiol; 2019 Mar; 56(3):2211-2223. PubMed ID: 30003517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of d-Peptides for Aβ Monomer Binding Specificity Enhances Their Potential to Eliminate Toxic Aβ Oligomers.
    Klein AN; Ziehm T; van Groen T; Kadish I; Elfgen A; Tusche M; Thomaier M; Reiss K; Brener O; Gremer L; Kutzsche J; Willbold D
    ACS Chem Neurosci; 2017 Sep; 8(9):1889-1900. PubMed ID: 28581708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surprisingly high stability of the Aβ oligomer eliminating all-d-enantiomeric peptide D3 in media simulating the route of orally administered drugs.
    Elfgen A; Santiago-Schübel B; Gremer L; Kutzsche J; Willbold D
    Eur J Pharm Sci; 2017 Sep; 107():203-207. PubMed ID: 28711713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Pharmacokinetic Studies of the Tritium Labelled D-Enantiomeric Peptide D3 Developed for the Treatment of Alzheimer´s Disease.
    Jiang N; Leithold LH; Post J; Ziehm T; Mauler J; Gremer L; Cremer M; Schartmann E; Shah NJ; Kutzsche J; Langen KJ; Breitkreutz J; Willbold D; Willuweit A
    PLoS One; 2015; 10(6):e0128553. PubMed ID: 26046986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Aβ oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology.
    van Groen T; Schemmert S; Brener O; Gremer L; Ziehm T; Tusche M; Nagel-Steger L; Kadish I; Schartmann E; Elfgen A; Jürgens D; Willuweit A; Kutzsche J; Willbold D
    Sci Rep; 2017 Nov; 7(1):16275. PubMed ID: 29176708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer's disease transgenic mice.
    Cao C; Cirrito JR; Lin X; Wang L; Verges DK; Dickson A; Mamcarz M; Zhang C; Mori T; Arendash GW; Holtzman DM; Potter H
    J Alzheimers Dis; 2009; 17(3):681-97. PubMed ID: 19581723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease.
    Zhang W; Hao J; Liu R; Zhang Z; Lei G; Su C; Miao J; Li Z
    Behav Brain Res; 2011 Sep; 222(2):342-50. PubMed ID: 21513747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease.
    Handattu SP; Garber DW; Monroe CE; van Groen T; Kadish I; Nayyar G; Cao D; Palgunachari MN; Li L; Anantharamaiah GM
    Neurobiol Dis; 2009 Jun; 34(3):525-34. PubMed ID: 19344763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multifunctional peptide rescues memory deficits in Alzheimer's disease transgenic mice by inhibiting Aβ42-induced cytotoxicity and increasing microglial phagocytosis.
    Xue D; Zhao M; Wang YJ; Wang L; Yang Y; Wang SW; Zhang R; Zhao Y; Liu RT
    Neurobiol Dis; 2012 Jun; 46(3):701-9. PubMed ID: 22426388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nobiletin, a citrus flavonoid, improves cognitive impairment and reduces soluble Aβ levels in a triple transgenic mouse model of Alzheimer's disease (3XTg-AD).
    Nakajima A; Aoyama Y; Shin EJ; Nam Y; Kim HC; Nagai T; Yokosuka A; Mimaki Y; Yokoi T; Ohizumi Y; Yamada K
    Behav Brain Res; 2015 Aug; 289():69-77. PubMed ID: 25913833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BHBA treatment improves cognitive function by targeting pleiotropic mechanisms in transgenic mouse model of Alzheimer's disease.
    Wu Y; Gong Y; Luan Y; Li Y; Liu J; Yue Z; Yuan B; Sun J; Xie C; Li L; Zhen J; Jin X; Zheng Y; Wang X; Xie L; Wang W
    FASEB J; 2020 Jan; 34(1):1412-1429. PubMed ID: 31914599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.